Global Obesity Treatment Market
Taille du marché en milliards USD
TCAC :
% 
USD
38.46 Million
USD
115.26 Million
2024
2032
 Période de prévision |
2025 –2032 |
 Taille du marché (année de référence) |
USD 38.46 Million |
 Taille du marché (année de prévision) |
USD 115.26 Million |
 TCAC |
% |
| Principaux acteurs du marché |
Segmentation du marché mondial du traitement de l'obésité, par type de traitement (traitements pharmacologiques (médicaments anti-obésité), chirurgie bariatrique, thérapie comportementale et de style de vie, procédures non invasives/endoscopiques et dispositifs et technologies médicaux), tranche d'âge (traitement de l'obésité adulte, traitement de l'obésité gériatrique et traitement de l'obésité pédiatrique), canal de distribution (pharmacies en ligne, pharmacies de détail, cliniques de gestion du poids, pharmacies hospitalières et centres de bien-être et de remise en forme), type de patient (classe III, classe II et classe I) - Tendances et prévisions du secteur jusqu'en 2032
Taille du marché du traitement de l'obésité
- Le marché mondial du traitement de l'obésité était évalué à 38,46 millions USD en 2024 et devrait atteindre 115,26 millions USD d'ici 2032.
- Au cours de la période de prévision de 2025 à 2032, le marché devrait croître à un TCAC de 14,7 %, principalement en raison de la prévalence croissante de l'obésité.
- Cette croissance est portée par des facteurs tels que les innovations dans les médicaments anti-obésité, le développement des chirurgies bariatriques et métaboliques, ainsi que l'intégration de solutions de santé numériques dans le traitement de l'obésité.
Analyse du marché du traitement de l'obésité
- L'obésité est une maladie chronique caractérisée par une accumulation excessive de graisse, augmentant le risque de complications de santé graves telles que les maladies cardiovasculaires, le diabète de type 2, l'hypertension et certains cancers.
- Les options de traitement vont des modifications du mode de vie, de la pharmacothérapie et des dispositifs médicaux à la chirurgie bariatrique, visant à obtenir une perte de poids durable et à améliorer les résultats de santé globaux.
- Le marché mondial du traitement de l'obésité est stimulé par la prévalence croissante de l'obésité due à la sédentarité, aux mauvaises habitudes alimentaires et aux prédispositions génétiques. Les interventions pharmacologiques, notamment les agonistes du récepteur GLP-1 et les coupe-faim, jouent un rôle crucial dans la gestion du poids, aux côtés des thérapies comportementales et des changements de mode de vie. Les chirurgies bariatriques, telles que le bypass gastrique et la sleeve gastrectomie, gagnent également en popularité comme solutions efficaces à long terme pour l'obésité sévère.
- La demande croissante de procédures mini-invasives et de médicaments innovants contre l'obésité stimule davantage la croissance du marché.
- L'Amérique du Nord demeure une région dominante sur le marché mondial du traitement de l'obésité, soutenue par une infrastructure de soins de santé bien établie, des taux d'obésité élevés et une recherche continue sur les solutions de gestion du poids.
- Par exemple, les États-Unis sont en tête dans l’adoption d’agonistes du récepteur GLP-1 comme le sémaglutide et le liraglutide, ainsi que dans les avancées dans les dispositifs médicaux non invasifs conçus pour la perte de poids.
- Avec l'accent croissant mis sur la gestion de l'obésité et les soins de santé préventifs, le marché mondial connaît des investissements importants dans de nouvelles thérapies, des technologies médicales et des solutions centrées sur le patient, stimulant ainsi l'expansion globale du secteur.
Portée du rapport et segmentation du marché du traitement de l'obésité
|
Attributs |
Aperçus clés du marché du traitement de l'obésité |
|
Segments couverts |
|
|
Pays couverts |
Amérique du Nord .
Europe
Asie-Pacifique
Amérique du Sud
Moyen-Orient et Afrique
|
|
Principaux acteurs du marché |
|
|
Opportunités de marché |
|
|
Ensembles d'informations de données à valeur ajoutée |
Outre les informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse des importations et des exportations, un aperçu de la capacité de production, une analyse de la consommation de production, une analyse des tendances des prix, un scénario de changement climatique, une analyse de la chaîne d'approvisionnement, une analyse de la chaîne de valeur, un aperçu des matières premières/consommables, des critères de sélection des fournisseurs, une analyse PESTLE, une analyse Porter et un cadre réglementaire. |
Tendances du marché du traitement de l'obésité
Adoption croissante de solutions de gestion du poids numériques et basées sur l'IA
- L’une des principales tendances du marché mondial du traitement de l’obésité est l’adoption croissante de solutions de gestion du poids numériques et basées sur l’IA.
- Ces technologies innovantes améliorent la gestion de l'obésité en fournissant des plans de traitement personnalisés, une surveillance en temps réel et des informations basées sur les données pour optimiser les stratégies de perte de poids.
- Par exemple, les applications mobiles et les appareils portables alimentés par l'IA suivent l'activité physique, l'apport calorique et les taux métaboliques, offrant des recommandations personnalisées pour améliorer l'observance et les résultats
- Les plateformes de télémédecine et le coaching virtuel soutiennent davantage les patients en proposant des consultations à distance, des conseils comportementaux et une gestion des médicaments, conduisant à une perte de poids plus efficace et plus durable.
- Cette tendance révolutionne les soins contre l'obésité en améliorant l'engagement des patients, en renforçant le succès du traitement à long terme et en stimulant la demande de solutions de santé numériques sur le marché du traitement de l'obésité.
Dynamique du marché du traitement de l'obésité
Conducteur
Prévalence croissante de l'obésité
- L'épidémie d'obésité s'aggrave en raison des modes de vie sédentaires, des mauvaises habitudes alimentaires et des prédispositions génétiques, ce qui entraîne une forte augmentation des complications de santé liées à l'obésité, telles que le diabète, les maladies cardiovasculaires et l'hypertension.
- L'urbanisation et les progrès technologiques ont contribué à réduire l'activité physique, tandis que la consommation généralisée d'aliments transformés et riches en calories a encore alimenté la prise de poids.
- Les facteurs génétiques jouent également un rôle important, de nombreuses personnes étant prédisposées aux troubles métaboliques contribuant à l'obésité. Face à la hausse constante des taux d'obésité, la demande de solutions thérapeutiques efficaces, notamment les thérapies pharmacologiques, la chirurgie bariatrique et les programmes de gestion du poids sous surveillance médicale, augmente considérablement.
Par exemple
- En mars 2024, selon les informations fournies par l'OMS, l'épidémie d'obésité s'aggrave en Europe : une personne sur huit est obèse en 2022. L'obésité chez les adultes a doublé depuis 1990 et celle chez les adolescents a quadruplé. Plus de 2,5 milliards d'adultes étaient en surpoids, dont 890 millions obèses. La hausse des taux d'obésité contribue à accroître les risques de diabète, de maladies cardiovasculaires et de cancer, ce qui stimule la demande de traitements efficaces et stimule la croissance du marché.
- En septembre 2024, comme le soulignent les Centres pour le contrôle et la prévention des maladies (CDC), entre août 2021 et août 2023, 40,3 % des adultes souffraient d'obésité, dont 39,2 % d'hommes et 41,3 % de femmes. La prévalence la plus élevée se situait chez les 40-59 ans (46,4 %), suivis des 20-39 ans (35,5 %) et des 60 ans et plus (38,9 %). L'augmentation du fardeau de l'obésité devrait stimuler la demande de traitements efficaces contre l'obésité.
- D'ici 2024, comme l'indique l'Atlas mondial de l'obésité, 79 % des adultes et 88 % des enfants en surpoids et obèses vivront dans des pays à revenu faible ou intermédiaire (PRFI) d'ici 2035. Le nombre d'adultes obèses devrait passer de 0,81 milliard en 2020 à 1,53 milliard en 2035. Cette prévalence croissante accroît la demande de solutions thérapeutiques pour l'obésité, stimulant ainsi la croissance du marché.
- Cette charge croissante pour les patients pousse les prestataires de soins de santé, les sociétés pharmaceutiques et les programmes de bien-être à élargir leurs offres, faisant de la prévalence croissante de l'obésité un moteur clé pour le marché européen du traitement de l'obésité.
Opportunité
Prévalence croissante des maladies liées au mode de vie
- Alors que de plus en plus de personnes cherchent à gérer leur poids et à atténuer les risques pour la santé qui y sont associés, les sociétés pharmaceutiques et les prestataires de soins de santé sont incités à innover et à élargir leurs offres.
- Cette tendance favorise le développement de nouveaux médicaments, d’options chirurgicales et de programmes de style de vie complets adaptés aux divers besoins des patients.
Par exemple
- En mai 2023, le NCBI a déclaré qu'il est estimé que plus d'un milliard de personnes vivront avec l'obésité d'ici 2030.1 Les taux plus élevés de mortalité et de comorbidités associées à l'obésité, telles que le diabète, les maladies cardiovasculaires, les maladies rénales chroniques et plusieurs types de cancer, sont tout aussi stupéfiants, avec une moyenne de 5 millions de décès et 160 millions d'années de vie ajustées sur l'incapacité.
- En juin 2023, selon un article publié par Acta Pharmaceutica Sinica B, l'obésité contribue fortement au développement du cancer, des maladies cardiovasculaires, du diabète de type 2, des maladies du foie et d'autres troubles
- En avril 2021, selon un article publié dans les American Heart Association Journals, l'obésité contribue directement aux facteurs de risque cardiovasculaire, notamment la dyslipidémie, le diabète de type 2, l'hypertension et les troubles du sommeil. Elle favorise également le développement de maladies cardiovasculaires et la mortalité par maladies cardiovasculaires, indépendamment des autres facteurs de risque cardiovasculaire.
- En avril 2023, une étude de MoneyControl a souligné que l'Inde a connu une augmentation massive des maladies liées au mode de vie, notamment une augmentation de la prévalence de facteurs de risque précoces comme l'obésité et les irrégularités du cholestérol.
- De plus, une sensibilisation accrue aux conséquences de l'obésité sur la santé encourage les consommateurs à adopter une gestion proactive de leur santé. Grâce aux initiatives des gouvernements et des organismes de santé promouvant des modes de vie plus sains, le marché du traitement de l'obésité est promis à une croissance substantielle.
- Cette dynamique attire les investissements et stimule les efforts de recherche et développement, ouvrant la voie à un large éventail d'interventions thérapeutiques pour répondre aux besoins d'une population de patients en expansion.
Retenue/Défi
Suivis à long terme associés au traitement de l'obésité
- Les suivis à long terme associés au traitement de l'obésité, principalement en raison de la complexité et de l'intensité des ressources de ces programmes, nécessitent souvent une surveillance et un soutien continus pour garantir une perte et une gestion durables du poids, ce qui peut inclure des consultations régulières, des conseils nutritionnels et une thérapie comportementale.
- Ces engagements à long terme pèsent sur les systèmes de santé et posent des défis logistiques tant aux patients qu'aux prestataires de soins, ce qui entraîne des lacunes potentielles dans les soins et une observance incohérente du traitement.
Par exemple
- En décembre 2022, selon l'AJMC, la prise en charge de l'obésité nécessite un partenariat continu entre un patient engagé et des cliniciens informés.
- En septembre 2022, le JAMA Network a rapporté que, dans une étude menée auprès de 175 patients, 94 (53,7 %) avaient perdu au moins 5 % de leur poids et 26 (14,9 %) 10 % ou plus à 3 mois. Sur 102 patients suivis pendant 6 mois, 89 (87,3 %) ont perdu 5 % ou plus de leur poids, 56 (54,9 %) 10 % ou plus de leur poids, 24 (23,5 %) 15 % ou plus de leur poids et 8 (7,8 %) 20 % ou plus de leur poids.
- En novembre 2021, selon un article publié par la Bibliothèque nationale de médecine, assurer un suivi à long terme semble primordial pour les patients en chirurgie bariatrique. Un suivi de mauvaise qualité en chirurgie bariatrique est considéré comme un facteur de risque de mauvais résultats, mais la polyvalence et l'efficacité du suivi sont également des facteurs déterminants pour la recherche clinique.
- De plus, la nécessité d'un suivi à long terme dissuade les patients de recourir à un traitement initial. De nombreux patients potentiels peuvent appréhender l'engagement et les coûts liés à des visites et un suivi réguliers, perçus comme intimidants ou contraignants.
- Cette hésitation freine la croissance du marché, car les consommateurs potentiels évitent les programmes qui nécessitent un engagement et une responsabilité soutenus.
- Par conséquent, le défi de faciliter des suivis efficaces à long terme peut limiter l’efficacité globale des traitements contre l’obésité et leur acceptation au sein de la population cible.
Portée du marché du traitement de l'obésité
Le marché est segmenté en fonction du type, du type de produit, du site d'absorption, de la tranche d'âge, de la source, du mode de livraison, du sexe et du canal de distribution.
|
Segmentation |
Sous-segmentation |
|
|
|
|
|
|
|
|
Analyse régionale du marché du traitement de l'obésité
L'Amérique du Nord est la région dominante sur le marché de l'insuline pour le diabète de type 1 et de type 2
- L'Amérique du Nord est en tête du marché mondial du traitement de l'obésité, grâce à une forte prévalence de l'obésité, une infrastructure de soins de santé avancée et une forte adoption de solutions innovantes de gestion du poids.
- Les États-Unis détiennent une part de marché importante en raison de la demande croissante de traitements pharmacologiques tels que les agonistes des récepteurs GLP-1, les chirurgies bariatriques et les plateformes numériques de gestion du poids.
- En outre, la sensibilisation croissante aux risques pour la santé liés à l'obésité et l'adoption croissante de programmes de perte de poids basés sur l'IA, de consultations de télésanté et de solutions de traitement non invasives continuent de stimuler l'expansion du marché dans la région.
L'Amérique du Sud devrait enregistrer le taux de croissance le plus élevé
- La région sud-américaine devrait connaître le taux de croissance le plus élevé sur le marché mondial du traitement de l’obésité, grâce à la prévalence croissante de l’obésité, à l’augmentation des investissements dans les soins de santé et à la sensibilisation croissante aux solutions de gestion du poids.
- Des pays comme le Brésil, l’Argentine et le Chili émergent comme des marchés clés en raison de l’évolution des modes de vie, de l’urbanisation croissante et du nombre croissant de complications de santé liées à l’obésité.
- Le Brésil, avec son infrastructure de santé en expansion et sa demande croissante en traitements médicaux pour la perte de poids, demeure un marché crucial pour la gestion de l'obésité. Le pays constate une adoption croissante des traitements pharmacologiques, des chirurgies bariatriques et des programmes numériques de gestion du poids.
Part de marché du traitement de l'obésité
Le paysage concurrentiel du marché fournit des détails par concurrent. Il comprend la présentation de l'entreprise, ses données financières, son chiffre d'affaires, son potentiel de marché, ses investissements en recherche et développement, ses nouvelles initiatives commerciales, sa présence mondiale, ses sites et installations de production, ses capacités de production, ses forces et faiblesses, le lancement de nouveaux produits, leur ampleur et leur portée, ainsi que la domination de ses applications. Les données ci-dessus ne concernent que les activités des entreprises par rapport à leur marché.
Les principaux leaders du marché opérant sur le marché sont :
- Novo Nordisk A/S (Danemark)
- Eli Lilly and Company (États-Unis)
- Medtronic (États-Unis)
- Boston Scientific Corporation (États-Unis)
- Johnson & Johnson Services, Inc. (États-Unis)
- Altimmune (États-Unis)
- AstraZeneca (Royaume-Uni)
- Allurion (États-Unis)
- Amgen Inc. (États-Unis)
- Arena Pharmaceuticals Ltd (États-Unis)
- Currax Pharmaceuticals LLC (États-Unis)
- CHIRURGIE COUSIN (France)
- F. Hoffmann-La Roche SA (Suisse)
- Fitterfly Healthtech Pvt. Ltd. (Inde)
- Morphic Medical, Inc (États-Unis)
- Noom, Inc. (États-Unis)
- Omada Health Inc (États-Unis)
- Reshape Lifesciences Inc. (États-Unis)
- Raziel (Israël)
- Spatz FGIA Inc. (États-Unis)
- Sanofi (France)
- Saniona (Danemark)
- USGI Medical (États-Unis)
- VIVUS LLC. (États-Unis)
- Viking Therapeutics (États-Unis)
Derniers développements sur le marché mondial du traitement de l'obésité
- En octobre 2024, VIVUS et UpScriptHealth ont lancé ChooseQ. online, une plateforme de télésanté offrant un accès pratique à QSYMIA pour la gestion du poids. Ce service permet aux patients de consulter des professionnels de santé en ligne et de recevoir QSYMIA directement à domicile. Cette initiative vise à améliorer l'accessibilité au traitement de l'obésité par la télémédecine.
- En octobre 2024, Zealand Pharma a annoncé que Boehringer Ingelheim avait reçu la désignation de « thérapie révolutionnaire » de la FDA américaine pour le Survodutide (BI 456906) dans le traitement de la stéatohépatite non cirrhotique associée à un dysfonctionnement métabolique (MASH) avec fibrose modérée ou avancée. Cette désignation accélère son développement grâce à des résultats prometteurs de phase II.
- En mars 2025, Zealand Pharma a annoncé la fin du recrutement des participants à l'essai de phase IIb ZUPREME-1 sur le pétrélintide, un analogue de l'amyline à action prolongée destiné au traitement du surpoids et de l'obésité. Cet essai évaluera les effets de différentes doses de pétrélintide sur le poids corporel, la sécurité d'emploi et la tolérance sur une période de 42 semaines. Les résultats sont attendus en 2025.
- En mars 2025, Raziel Therapeutics, une société pharmaceutique spécialisée dans les produits de prescription de nouvelle génération destinés au marché de l'esthétique médicale, a annoncé le lancement d'une étude clinique de phase 3 en Chine pour le RZL-012, visant à réduire la graisse sous-mentonnière (GSM). La réduction de la GSM est la première indication du RZL-012, avec des applications potentielles pour divers traitements esthétiques de réduction de la graisse dans le remodelage corporel.
- En octobre 2022, ReShape Lifesciences, leader des solutions de perte de poids et de santé métabolique, a annoncé que l'American Society for Metabolic and Bariatric Surgery (ASMBS) et la Fédération internationale de chirurgie de l'obésité et des troubles métaboliques (IFSO) avaient publié des recommandations actualisées pour la chirurgie métabolique et bariatrique, qui incluent désormais l'anneau gastrique. Ces recommandations remplacent les normes établies il y a 30 ans par les National Institutes of Health (NIH) en 1991.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL OBESITY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 EPIDEMIOLOGY: GLOBAL OBESITY TREATMENT MARKET
4.4 DRUG TREATMENT RATE BY MATURED MARKETS: GLOBAL OBESITY TREATMENT MARKET
4.5 DRUG
4.6 WORD PIPELINE
5 REGULATORY FRAMEWORK FOR THE GLOBAL OBESITY TREATMENT MARKET
5.1 REGULATORY APPROVAL PATHWAYS
5.2 LICENSING AND REGISTRATION
5.3 REGULATORY APPROVAL PATHWAYS
5.4 LICENSING AND REGISTRATION
5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF OBESITY
6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS
6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES.
6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT
6.2 RESTRAINTS
6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS
6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY
6.3 OPPORTUNITIES
6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES
6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS
6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT
6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES
7 GLOBAL OBESITY TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS)
7.2.1 GLP-1 RECEPTOR AGONISTS
7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS
7.2.2.1 PHENTERMINE
7.2.2.2 PHENTERMINE-TOPIRAMATE
7.2.2.3 NALTREXONE-BUPROPION
7.2.3 LIPASE INHIBITORS
7.2.4 DEOXYCHOLIC ACID
7.2.5 OTHERS
7.3 BARIATRIC SURGERY
7.3.1 RESTRICTIVE SURGERIES
7.3.1.1 SLEEVE GASTRECTOMY
7.3.1.2 ADJUSTABLE GASTRIC BANDING
7.3.2 COMBINATION SURGERIES
7.3.2.1 ROUX-EN-Y GASTRIC BYPASS (RYGB)
7.3.2.2 MINI-GASTRIC BYPASS (MGB)
7.3.3 MALABSORPTIVE SURGERIES
7.3.3.1 LAPAROSCOPIC SURGERY
7.3.3.2 ROBOTIC-ASSISTED SURGERY
7.3.3.3 OPEN SURGERY
7.4 BEHAVIORAL & LIFESTYLE THERAPY
7.4.1 DIETARY INTERVENTIONS
7.4.2 BEHAVIORAL MODIFICATION THERAPY
7.4.3 PHYSICAL ACTIVITY PROGRAMS
7.4.4 PSYCHOLOGICAL COUNSELING
7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES
7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG)
7.5.2 INTRAGASTRIC BALLOON (IGB)
7.5.2.1 ORBERA INTRAGASTRIC BALLOON
7.5.2.2 SPATZ ADJUSTABLE BALLOON SYSTEM
7.5.3 ASPIRATION THERAPY (ASPIREASSIST)
7.5.4 TRANSORAL GASTROPLASTY (TOGA)
7.6 MEDICAL DEVICES & TECHNOLOGIES
7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS
7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM)
8 GLOBAL OBESITY TREATMENT MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 ADULT OBESITY TREATMENT
8.3 GERIATRIC OBESITY TREATMENT
8.4 PEDIATRIC OBESITY TREATMENT
9 GLOBAL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 ONLINE PHARMACIES
9.3 RETAIL PHARMACIES
9.4 WEIGHT MANAGEMENT CLINICS
9.5 HOSPITAL PHARMACIES
9.6 WELLNESS & FITNESS CENTERS
10 GLOBAL OBESITY TREATMENT MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 CLASS III
10.3 CLASS II
10.4 CLASS I
11 GLOBAL OBESITY TREATMENT MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 MEXICO
11.2.3 CANADA
11.3 EUROPE
11.3.1 UNITED KINGDOM
11.3.2 GERMANY
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 RUSSIA
11.3.7 TURKEY
11.3.8 NETHERLANDS
11.3.9 SWITZERLAND
11.3.10 POLAND
11.3.11 IRELAND
11.3.12 AUSTRIA
11.3.13 NORWAY
11.3.14 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 TAIWAN
11.4.7 SINGAPORE
11.4.8 MALAYSIA
11.4.9 THAILAND
11.4.10 INDONESIA
11.4.11 PHILIPPINES
11.4.12 VIETNAM
11.4.13 REST OF ASIA-PACIFIC
11.5 MIDDLE EAST AND AFRICA
11.5.1 SAUDI ARABIA
11.5.2 EGYPT
11.5.3 KUWAIT
11.5.4 SOUTH AFRICA
11.5.5 UNITED ARAB EMIRATES
11.5.6 ISRAEL
11.5.7 REST OF MIDDLE EAST AND AFRICA
11.6 SOUTH AMERICA
11.6.1 BRAZIL
11.6.2 ARGENTINA
11.6.3 CHILE
11.6.4 PERU
11.6.5 REST OF SOUTH AMERICA
12 GLOBAL OBESITY TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 NOVO NORDISK A/S
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ELI LILLY AND COMPANY
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT/NEWS
14.3 MEDTRONIC
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION
14.4.1 COMPANY SNAPSHOTS
14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 JOHNSON & JOHNSON SERVICES, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT/NEWS
14.6 ALTIMMUNE
14.6.1 COMPANY SNAPSHOT
14.6.2 PIPELINE PORTFOLIO
14.6.3 RECENT UPDATES
14.7 ASTRAZENECA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT/NEWS
14.8 ALLURION
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
1.1.5 RECENT DEVELOPMENT/NEWS 421
14.9 AMGEN
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
1.1.13 RECENT DEVELOPMENT/NEWS 426
14.1 ARENA PHARMACEUTICALS LTD
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 CURRAX PHARMACEUTICALS LLC
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 COUSIN SURGERY
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 F. HOFFMANN-LA ROCHE LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT/NEWS
14.14 FITTERFLY HEALTHTECH PVT. LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MORPHIC MEDICAL, INC
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 NOOM, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 OMADA HEALTH INC
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 RESHAPE LIFESCIENCES
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
1.1.7 RECENT DEVELOPMENT/NEWS 445
14.19 RAZIEL
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 SPATZ FGIA INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 SANOFI
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
14.22 SANIONA
14.22.1 COMPANY SNAPSHOT
14.22.2 REVENUE ANALYSIS
14.22.3 PRODUCT PORTFOLIO
14.22.4 RECENT DEVELOPMENT
14.23 USGI MEDICAL
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENT
14.24 VIVUS LLC.
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENT/NEWS
14.25 VIKING THERAPEUTICS
14.25.1 COMPANY SNAPSHOTS
14.25.2 REVENUE ANALYSIS
14.25.3 PRODUCT PORTFOLIO
14.25.4 RECENT DEVELOPMENT
14.26 ZEALAND PHARMA
14.26.1 COMPANY SNAPSHOT
14.26.2 REVENUE ANALYSIS
14.26.3 PRODUCT PORTFOLIO
14.26.4 RECENT DEVELOPMENT/NEWS
15 QUESTIONNAIRE
16 RELATED REPORTS
Liste des tableaux
TABLE 1 OBESITY PREVALENCE BY REGION (ADULTS)
TABLE 2 OBESITY PREVALENCE BY GENDER (ADULTS)
TABLE 3 OBESITY PREVALENCE BY AGE (ADULTS)
TABLE 4 GLOBAL CLINICAL TRIAL MARKET FOR OBESITY TREATMENT
TABLE 5 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL OBESITY TREATMENT MARKET
TABLE 6 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE GLOBAL OBESITY TREATMENT MARKET
TABLE 7 GLOBAL OBESITY STATISTICS (2022)
TABLE 8 GLOBAL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 GLOBAL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL ADULT OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL GERIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL PEDIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL ONLINE PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL RETAIL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL WEIGHT MANAGEMENT CLINICS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL HOSPITAL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 GLOBAL WELLNESS & FITNESS CENTERS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 GLOBAL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 GLOBAL CLASS III IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 GLOBAL CLASS II IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 GLOBAL CLASS I IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 GLOBAL OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 U.S. OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 U.S. PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 U.S. CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 U.S. RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 U.S. COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 60 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 61 U.S. BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 U.S. NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 U.S. INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 U.S. MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 U.S OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 66 U.S. OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 67 U.S. OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MEXICO OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MEXICO PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 MEXICO CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 MEXICO RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MEXICO COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 74 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 75 MEXICO BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MEXICO NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MEXICO INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 MEXICO MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 MEXICO OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 80 MEXICO OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 81 MEXICO OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 CANADA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 CANADA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 CANADA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 CANADA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 CANADA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 88 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 89 CANADA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 CANADA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 CANADA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 CANADA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 CANADA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 94 CANADA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 95 CANADA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 EUROPE OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 97 EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 EUROPE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 EUROPE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 EUROPE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 EUROPE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 103 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 104 EUROPE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 EUROPE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 EUROPE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 EUROPE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 EUROPE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 109 EUROPE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 110 EUROPE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 UNITED KINGDOM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 UNITED KINGDOM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 UNITED KINGDOM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 UNITED KINGDOM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 UNITED KINGDOM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 117 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 118 UNITED KINGDOM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 UNITED KINGDOM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 UNITED KINGDOM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 UNITED KINGDOM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 UNITED KINGDOM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 123 UNITED KINGDOM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 124 UNITED KINGDOM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 GERMANY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 GERMANY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 GERMANY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 GERMANY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 GERMANY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 131 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 132 GERMANY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 GERMANY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 GERMANY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 GERMANY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 GERMANY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 137 GERMANY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 138 GERMANY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 FRANCE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 FRANCE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 FRANCE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 FRANCE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 FRANCE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 145 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 146 FRANCE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 FRANCE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 FRANCE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 FRANCE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 FRANCE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 151 FRANCE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 152 FRANCE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 ITALY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 ITALY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 ITALY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 ITALY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 ITALY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 159 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 160 ITALY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 ITALY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 ITALY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 ITALY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 ITALY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 165 ITALY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 166 ITALY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 SPAIN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 SPAIN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 SPAIN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 SPAIN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 SPAIN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 173 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 174 SPAIN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 SPAIN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 SPAIN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 SPAIN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 SPAIN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 179 SPAIN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 180 SPAIN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 RUSSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 RUSSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 RUSSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 RUSSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 RUSSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 187 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 188 RUSSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 RUSSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 RUSSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 RUSSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 RUSSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 193 RUSSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 194 RUSSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 TURKEY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 TURKEY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 TURKEY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 TURKEY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 TURKEY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 201 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 202 TURKEY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 TURKEY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 TURKEY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 TURKEY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 TURKEY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 207 TURKEY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 208 TURKEY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 NETHERLANDS OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 NETHERLANDS PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 NETHERLANDS CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 213 NETHERLANDS RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 NETHERLANDS COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 215 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 216 NETHERLANDS BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 NETHERLANDS NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 NETHERLANDS INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 NETHERLANDS MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 NETHERLANDS OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 221 NETHERLANDS OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 222 NETHERLANDS OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 SWITZERLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 SWITZERLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 SWITZERLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 SWITZERLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 SWITZERLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 229 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 230 SWITZERLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 SWITZERLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 SWITZERLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 SWITZERLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 SWITZERLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 235 SWITZERLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 236 SWITZERLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 POLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 POLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 POLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 POLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 POLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 243 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 244 POLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 POLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 POLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 POLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 POLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 249 POLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 250 POLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 IRELAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 IRELAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 IRELAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 IRELAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 IRELAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 257 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 258 IRELAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 IRELAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 IRELAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 IRELAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 IRELAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 263 IRELAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 264 IRELAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 AUSTRIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 AUSTRIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 AUSTRIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 AUSTRIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 AUSTRIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 271 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 272 AUSTRIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 AUSTRIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 AUSTRIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 AUSTRIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 AUSTRIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 277 AUSTRIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 278 AUSTRIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 NORWAY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 NORWAY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 NORWAY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 NORWAY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 NORWAY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 285 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 286 NORWAY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 NORWAY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 NORWAY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 NORWAY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 NORWAY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 291 NORWAY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 292 NORWAY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 REST OF EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 295 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 ASIA-PACIFIC PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 ASIA-PACIFIC CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 ASIA-PACIFIC RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 ASIA-PACIFIC COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 301 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 302 ASIA-PACIFIC BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 303 ASIA-PACIFIC NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 ASIA-PACIFIC INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 ASIA-PACIFIC MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 307 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 308 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 CHINA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 CHINA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 CHINA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 CHINA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 314 CHINA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 315 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 316 CHINA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 CHINA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 CHINA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 CHINA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 CHINA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 321 CHINA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 322 CHINA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 JAPAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 JAPAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 JAPAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 JAPAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 JAPAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 329 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 330 JAPAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 JAPAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 JAPAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 JAPAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 JAPAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 335 JAPAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 336 JAPAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 INDIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 INDIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 INDIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 341 INDIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 INDIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 343 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 344 INDIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 INDIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 INDIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 INDIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 INDIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 349 INDIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 350 INDIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 AUSTRALIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 AUSTRALIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 AUSTRALIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 AUSTRALIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 AUSTRALIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 357 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 358 AUSTRALIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 AUSTRALIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 AUSTRALIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 AUSTRALIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 AUSTRALIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 363 AUSTRALIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 364 AUSTRALIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 SOUTH KOREA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 SOUTH KOREA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 SOUTH KOREA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 SOUTH KOREA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 SOUTH KOREA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 371 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 372 SOUTH KOREA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 SOUTH KOREA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 SOUTH KOREA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 SOUTH KOREA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SOUTH KOREA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 377 SOUTH KOREA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 378 SOUTH KOREA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 TAIWAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 380 TAIWAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 TAIWAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 TAIWAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 TAIWAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 385 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 386 TAIWAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 TAIWAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 TAIWAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 TAIWAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 TAIWAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 391 TAIWAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 392 TAIWAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 SINGAPORE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 SINGAPORE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 SINGAPORE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 SINGAPORE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 SINGAPORE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 399 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 400 SINGAPORE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 SINGAPORE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 SINGAPORE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 SINGAPORE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 SINGAPORE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 405 SINGAPORE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 406 SINGAPORE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 MALAYSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 MALAYSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 MALAYSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 MALAYSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 MALAYSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 413 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 414 MALAYSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 MALAYSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 MALAYSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 MALAYSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 MALAYSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 419 MALAYSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 420 MALAYSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 THAILAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 THAILAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 THAILAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 THAILAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 THAILAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 427 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 428 THAILAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 THAILAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 THAILAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 THAILAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 THAILAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 433 THAILAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 434 THAILAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 INDONESIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 INDONESIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 INDONESIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 439 INDONESIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 INDONESIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 441 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 442 INDONESIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 INDONESIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 444 INDONESIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 445 INDONESIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 446 INDONESIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 447 INDONESIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 448 INDONESIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 PHILIPPINES OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 PHILIPPINES PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 PHILIPPINES CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 PHILIPPINES RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 PHILIPPINES COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 455 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 456 PHILIPPINES BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 PHILIPPINES NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 PHILIPPINES INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 PHILIPPINES MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 PHILIPPINES OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 461 PHILIPPINES OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 462 PHILIPPINES OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 VIETNAM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 VIETNAM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 VIETNAM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 VIETNAM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 468 VIETNAM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 469 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 470 VIETNAM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 471 VIETNAM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 VIETNAM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 VIETNAM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 VIETNAM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 475 VIETNAM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 476 VIETNAM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 REST OF ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 479 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 MIDDLE EAST AND AFRICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 MIDDLE EAST AND AFRICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 MIDDLE EAST AND AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 MIDDLE EAST AND AFRICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 MIDDLE EAST AND AFRICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 485 MIDDLE EAST AND AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 486 MIDDLE EAST AND AFRICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 MIDDLE EAST AND AFRICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 MIDDLE EAST AND AFRICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 MIDDLE EAST AND AFRICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 491 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 492 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 SAUDI ARABIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 494 SAUDI ARABIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 495 SAUDI ARABIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 496 SAUDI ARABIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 SAUDI ARABIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 498 SAUDI ARABIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 499 SAUDI ARABIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 500 SAUDI ARABIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 SAUDI ARABIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 SAUDI ARABIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 SAUDI ARABIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 SAUDI ARABIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 505 SAUDI ARABIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 506 SAUDI ARABIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 EGYPT OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 EGYPT PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 EGYPT CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 EGYPT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 EGYPT RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 EGYPT COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 513 EGYPT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 514 EGYPT BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 EGYPT NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 516 EGYPT INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 EGYPT MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 518 EGYPT OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 519 EGYPT OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 520 EGYPT OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 KUWAIT OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 KUWAIT PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 KUWAIT CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 KUWAIT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 KUWAIT RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 KUWAIT COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 527 KUWAIT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 528 KUWAIT BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 KUWAIT NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 KUWAIT INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 KUWAIT MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 KUWAIT OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 533 KUWAIT OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 534 KUWAIT OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 SOUTH AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 536 SOUTH AFRICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 SOUTH AFRICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 538 SOUTH AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 539 SOUTH AFRICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 SOUTH AFRICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 541 SOUTH AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 542 SOUTH AFRICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 SOUTH AFRICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 544 SOUTH AFRICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 545 SOUTH AFRICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 SOUTH AFRICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 547 SOUTH AFRICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 548 SOUTH AFRICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 UNITED ARAB EMIRATES PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 UNITED ARAB EMIRATES CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 UNITED ARAB EMIRATES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 UNITED ARAB EMIRATES RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 UNITED ARAB EMIRATES COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 555 UNITED ARAB EMIRATES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 556 UNITED ARAB EMIRATES BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 UNITED ARAB EMIRATES NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 UNITED ARAB EMIRATES INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 UNITED ARAB EMIRATES MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 561 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 562 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 563 ISRAEL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 564 ISRAEL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 ISRAEL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 ISRAEL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 ISRAEL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 ISRAEL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 569 ISRAEL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 570 ISRAEL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 ISRAEL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 ISRAEL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 ISRAEL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 ISRAEL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 575 ISRAEL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 576 ISRAEL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 REST OF MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 SOUTH AMERICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 579 SOUTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 580 SOUTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 581 SOUTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 582 SOUTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 583 SOUTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 584 SOUTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 585 SOUTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 586 SOUTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 SOUTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 588 SOUTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 589 SOUTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 SOUTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 591 SOUTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 592 SOUTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 BRAZIL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 BRAZIL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 BRAZIL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 BRAZIL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 BRAZIL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 BRAZIL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 599 BRAZIL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 600 BRAZIL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 BRAZIL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 BRAZIL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 603 BRAZIL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 BRAZIL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 605 BRAZIL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 606 BRAZIL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 ARGENTINA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 ARGENTINA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 ARGENTINA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 ARGENTINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 ARGENTINA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 ARGENTINA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 613 ARGENTINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 614 ARGENTINA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 ARGENTINA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 ARGENTINA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 ARGENTINA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 ARGENTINA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 619 ARGENTINA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 620 ARGENTINA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 CHILE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 CHILE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 CHILE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 624 CHILE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 CHILE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 CHILE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 627 CHILE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 628 CHILE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 CHILE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 CHILE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 CHILE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 632 CHILE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 633 CHILE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 634 CHILE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 PERU OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 PERU PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 PERU CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 PERU BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 PERU RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 PERU COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 641 PERU BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 642 PERU BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 643 PERU NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 PERU INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 PERU MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 PERU OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 647 PERU OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 648 PERU OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 649 REST OF SOUTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
Liste des figures
FIGURE 1 GLOBAL OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL OBESITY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL OBESITY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL OBESITY TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL OBESITY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL OBESITY TREATMENT MARKET: LIFELINE CURVE
FIGURE 7 GLOBAL OBESITY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL OBESITY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL OBESITY TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 GLOBAL OBESITY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 12 GLOBAL OBESITY TREATMENT MARKET EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 FIVE SEGMENTS COMPRISE THE GLOBAL OBESITY TREATMENT MARKET , BY TREATMENT TYPE
FIGURE 15 RISING PREVALENCE OF OBESITY IS EXPECTED TO DRIVE THE GROWTH OF GLOBAL OBESITY TREATMENT MARKET FROM 2025 TO 2032
FIGURE 16 THE PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OBESITY TREATMENT MARKET IN 2025 - 2032
FIGURE 17 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL OBESITY TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 18 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL OBESITY TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 19 MARKET OVERVIEW
FIGURE 20 PREVALENCE OF OBESITY IN ADULTS AGE 20 AND OLDER, BY SEX AND AGE: UNITED STATES, AUGUST 2021–AUGUST 2023 SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION.
FIGURE 21 SHARE OF PRE-OBESE AND OBESE PERSONS AGED 16 YEARS OR OVER, BY SEX, 2022 (%)
FIGURE 22 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 23 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 24 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 25 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 26 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 27 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)
FIGURE 28 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 29 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 31 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 32 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 33 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2024
FIGURE 35 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 36 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, CAGR (2025-2032)
FIGURE 37 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 38 GLOBAL OBESITY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 39 GLOBAL OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 40 NORTH AMERICA OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 41 EUROPE OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 42 ASIA-PACIFIC OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
